Olaratumab

Drug Profile

Olaratumab

Alternative Names: Anti-PDGFRα mAb 3G3; IMC-3G3; Lartruvo; LY 3012207

Latest Information Update: 20 Jul 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator ImClone Systems
  • Developer Eli Lilly
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Platelet derived growth factor alpha receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Soft tissue sarcoma
  • New Molecular Entity Yes

Highest Development Phases

  • Registered Soft tissue sarcoma
  • Phase I/II Pancreatic cancer
  • Phase I Solid tumours
  • No development reported Gastrointestinal stromal tumours; Glioblastoma; Non-small cell lung cancer; Ovarian cancer; Prostate cancer

Most Recent Events

  • 05 Jul 2017 Phase-I clinical trials in Soft tissue sarcoma (Late-stage disease, Metastatic disease, Combination therapy, Second-line therapy or greater, Inoperable/Unresectable) in USA (IV) (NCT03126591)
  • 22 Jun 2017 Phase-I/II clinical trials in Pancreatic cancer (First-line therapy, Combination therapy, Metastatic disease) in USA, Germany (IV) (EudraCT2016-001099-31; NCT03086369)
  • 27 Mar 2017 Eli Lilly plans a phase I/II trial for Pancreatic cancer (Metastatic disease, Late-stage disease, Combination therapy, First-line therapy) in USA, Germany, Italy and Spain (NCT03086369)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top